ADAC LABS AVOIDS O-T-C DEVICE STOCKS' JUNE SWOON, GAINS 38.9% TO 22-3/4 WHILE INDEX SLIDES 7.6%; TARGET FALLS SHARPLY ON SUPREME COURT PREEMPTION RULING
This article was originally published in The Gray Sheet
ADAC Laboratories stock jumped 38.9% to 22-3/4 in June, as enthusiasm for its new technology in nuclear imaging sparked interest among investors and led the firm into the spotlight in the financial press. The stock's performance was a bright spot in an otherwise dismal month for NASDAQ-traded device stocks.
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.
Bridges Consumer Healthcare launched by former Sanofi executives gets its first brand by acquiring North American rights to Pfizer’s ThermaCare HeatWraps brand. Pfizer divested the brand so European regulators would give antitrust clearance to its consumer JV with GSK.